European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
Executive Summary
Dutch and Belgian health agencies will undertake a pilot project next year on jointly negotiating prices with pharma companies.
You may also be interested in...
European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure
One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.
France Seeks Stronger Cost-Effectiveness Tools To Lower Drug Prices, But Pan-European Bulk Buying May Come First
France’s drugs assessment agency wants simpler, stronger rules to evaluate the cost-effectiveness of new drugs. But changes to the country’s complex reimbursement system may be too slow to address immediate budget concerns, making pan-European bulk buying appear a more likely near-term solution.
European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs
The EU’s Health Commissioner called for an open debate on pharmaceutical pricing with industry, while Guido Rasi prepares for part two of helming the European Medicines Agency and German big pharmas Bayer and Merck KGaA completed business restructuring. More developments in this month's column.